4.6 Review

Progranulin in Musculoskeletal Inflammatory and Degenerative Disorders, Focus on Rheumatoid Arthritis, Lupus and Intervertebral Disc Disease: A Systematic Review

期刊

PHARMACEUTICALS
卷 15, 期 12, 页码 -

出版社

MDPI
DOI: 10.3390/ph15121544

关键词

progranulin; inflammatory diseases; rheumatoid arthritis; lupus; intervertebral disc disease

资金

  1. ISCIII [RD21/0002/0025, PI20/00902, PI21/01145, CB16/11/00226]
  2. FEDER [Exp.18/00188, CD21/00042]
  3. Research Executive Agency of the European Union in the framework of MSCA- RISE Action of the H2020 Programme [734899]
  4. Xunta de Galicia, Conselleria de Educacion, Universidade e Formacion Profesional and Conselleria de Economia, Emprego e Industria (GAIN) [GPC IN607B2022/03]
  5. Xunta de Galicia [IN606A-2020/010]
  6. Secretaria de Estado de Universidades, Investigacion, Desarrollo e Innovacion, Ministerio de Universidades [FPU2018-04165]

向作者/读者索取更多资源

Progranulin (PGRN) is a glycoprotein that plays an important role in immunity, inflammatory response, and tissue recovery. It has become an important target for research in musculoskeletal inflammatory diseases such as rheumatoid arthritis, systemic lupus erythematosus, and intervertebral disc degeneration. This review systematically summarizes recent findings on the role of PGRN in the development and resolution of inflammatory diseases.
Progranulin (PGRN) is a glycoprotein formed by 593 amino acids encoded by the GRN gene. It has an important role in immunity and inflammatory response, as well as in tissue recovery. Its role in musculoskeletal inflammatory diseases such as rheumatoid arthritis (RA), systemic lupus erythematosus (SLE) and intervertebral disc degeneration disease (IVDD), is, nowadays, an important target to investigate. The objective of this review is to systematically sum up all the recent findings concerning PGRN as a target in the development and resolution of the inflammatory diseases. PubMed was examined with the terms combinations (Progranulin) AND (Lupus Erythematosus, Systemic), (Progranulin) AND (Arthritis, Rheumatoid), and (Progranulin) AND (Intervertebral Disc Degeneration). PubMed was examined with the terms combinations (Atsttrin) AND (Lupus Erythematosus, Systemic), (Atsttrin) AND (Arthritis, Rheumatoid), and (Atsttrin) AND (Intervertebral Disc Degeneration). Moreover, research through Web of Science was performed searching the same items. The inclusion criteria were: studies whose main topic were progranulin, or atsttrin, with emphasis on the three selected diseases. On the other hand, the exclusion criteria were studies that only focused on diseases not related to RA, lupus or IVDD, in addition to the previous published literature reviews. Since few results were obtained, we did not filter by year. The records assessed for eligibility were 23, including all the studies with the information in state of art of progranulin and its capability to be a potential target or treatment for each one of the selected diseases. As these results are descriptive and not clinical trials, we did not perform risk of bias methods. Within these results, many studies have shown an anti-inflammatory activity of PGRN in RA. PGRN levels in serum and synovial fluids in RA patients were reported higher than controls. On the other hand, serum levels were directly correlated with SLE disease activity index, suggesting an important role of PGRN as a player in the progression of inflammatory diseases and a therapeutical approach for the recovery. This review has some limitations due to the small number of studies in this regard; therefore, we highlight the importance and the necessity of further investigation. No external funding was implicated in this systematical review.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据